StreetInsider.com News Articles

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire

Mon, 27 Jul 2026 09:01:05 -0400

Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.

The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus entry, where it has shown nanomolar to picomolar activity across known coronavirus strains. Its activity against Ebola Zaire, a filovirus responsible for 17 of the last 20 Ebola outbreaks, demonstrates the value of the

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Form PRE 14A Decoy Therapeutics Inc. For: Jul 24

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813570.html

Form PRE 14A Decoy Therapeutics Inc. For: Jul 24

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813570.html

Form EFFECT Decoy Therapeutics Inc.

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786498.html

Form EFFECT Decoy Therapeutics Inc.

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786498.html

Form 424B3 Decoy Therapeutics Inc.

Fri, 17 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260717/26785084.html

Form 424B3 Decoy Therapeutics Inc.

Fri, 17 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260717/26785084.html

Form 8-K Decoy Therapeutics Inc. For: Jul 14

Wed, 15 Jul 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260715/26774948.html

Form 8-K Decoy Therapeutics Inc. For: Jul 14

Wed, 15 Jul 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260715/26774948.html

Decoy Therapeutics elects Moderna executive to its board

Wed, 15 Jul 2026 09:25:39 -0400

Decoy Therapeutics Inc. (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the company's 2026 Annual Meeting of Stockholders, held July 14, 2026.

Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.

Gauthier has served as Senior Vice President and Regional Head for Australia, Canada, and the United Kingdom at Moderna since 2025, overseeing strategy and operations across biomanufacturing, national health security partnerships, and commercialization. She previously served as General Manager of Moderna Canada, where she helped oversee delivery of more than 50 million COVID-19

Decoy Therapeutics elects Moderna executive to its board

Wed, 15 Jul 2026 09:25:39 -0400

Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.

Decoy Therapeutics elects Moderna executive to its board

Wed, 15 Jul 2026 09:25:39 -0400

Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.

Decoy Therapeutics elects Moderna executive to its board

Wed, 15 Jul 2026 09:25:39 -0400

Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors